| 1937: First cases of LAM [8] |
| 1966, 1975: Comprehensive description of LAM patients [6, 7] |
| 1995–2000: Retrospective studies [9–13] |
| 1993: Identification of the TSC2 gene coding for tuberin [14] |
| 1997: Identification of the TSC1 gene coding for hamartin [15] |
| 1997: National Heart Lung Blood Institute LAM registry [16] |
| 1998: TSC2 loss of heterozygosity in angiomyolipomas and lymph nodes from patients with LAM [17] |
| 2000: TSC2 mutations in renal and pulmonary LAM cells [18] |
| 2002: Activation of the mTOR pathway downstream of TSC genes in LAM [19] |
| 2003: Model of “metastasis” of LAM cells [20] |
| 2004: Isolation of circulating LAM cells from peripheral blood [21] |
| 2006: Increased level of serum vascular endothelial growth factor-D [22] |
| 2006: Sirolimus trial in pulmonary LAM (NCT00414648), results expected in 2011 |
| 2006: Efficacy of sirolimus on astrocytomas in tuberous sclerosis complex [23] |
| 2006–2007: Differential diagnosis of cystic lung disease, such as Birt–Hogg–Dubé and nonamyloid immunoglobulin deposition disease [24–26] |
| 2008: Sirolimus trial results in angiomyolipomas [27] |
| 2009: International everolimus trial in pulmonary LAM (NCT01059318) |